Abbott prices $20 billion of senior notes to help fund Exact Sciences acquisition
Abbott agreed under a pricing agreement dated February 23, 2026, to sell $20 billion of senior notes in several series maturing from 2029 to 2066. The company said it will use the proceeds, with cash on hand and possibly additional borrowings, to pay the consideration for its acquisition of Exact Sciences, repay certain Exact Sciences debt, cover fees and expenses, and for general corporate purposes. Closing of the sale is expected on March 9, 2026, subject to customary conditions.
Key points
- Total offering of $20 billion across eight series, including $1 billion of floating rate notes due 2029 and $3.75 billion each of 4.650% notes due 2036 and 5.500% notes due 2056
- Proceeds intended to fund the Exact Sciences acquisition consideration and repay certain Exact Sciences indebtedness
- Closing expected March 9, 2026, subject to customary closing conditions
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.